We are live on ! Find out more
TXG icon

10x Genomics

104 hedge funds and large institutions have $2.45B invested in 10x Genomics in 2020 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

209% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 11

122% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 18

84% more call options, than puts

Call options by funds: $8.79M | Put options by funds: $4.77M

37.33% more ownership

Funds ownership: 147.35%184.68% (+37%)

22% more funds holding

Funds holding: 85104 (+19)

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

4% more capital invested

Capital invested by funds: $2.35B → $2.45B (+$101M)

Holders
104
Holders Change
+19
Holders Change %
+22.35%
% of All Funds
2.29%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.13%
New
34
Increased
40
Reduced
18
Closed
11
Calls
$8.79M
Puts
$4.77M
Net Calls
+$4.02M
Net Calls Change
+$807K

TXG Hedge Fund Activity: Q1 2020 in Review

104 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2020, worth a combined $2.45B — up 4.3% from $2.35B a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new TXG positions and 11 closed out — a net gain of 23 holders — while 40 added to existing stakes and 18 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $309M. The largest seller was Foresite Capital Management I, cutting an estimated $113M.

  • 104 institutional investors held 10x Genomics (TXG) as of Q1 2020, up from 85 in Q4 2019.
  • Funds reported $2.45B of 10x Genomics stock for Q1 2020, up 4.3% quarter-over-quarter.
  • 34 funds opened new 10x Genomics positions in Q1 2020 and 11 closed out, a net change of +23 holders.
  • The largest 10x Genomics buyer in Q1 2020 was Morgan Stanley, an estimated $309M added.
  • The largest 10x Genomics seller in Q1 2020 was Foresite Capital Management I, an estimated $113M sold.

Based on aggregated 13F filings for Q1 2020.